US Broker Ratings

Phreesia, Inc. (PHR) Stock Analysis: Unlocking a Potential Upside of Nearly 137%

Phreesia, Inc. (PHR) is a key player in the healthcare technology sector, providing an innovative Software-as-a-Service (SaaS) platform that streamlines patient intake and payment processes. As the healthcare industry increasingly..

NewAmsterdam Pharma (NAMS) Stock Analysis: Potential 41% Upside Beckons Investors Despite Current Challenges

NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS), a Netherlands-based biopharmaceutical firm, is capturing investor interest with its promising yet challenging financial landscape. Specializing in the development of therapies for metabolic diseases,..

ARS Pharmaceuticals, Inc. (SPRY) Stock Analysis: Exploring a Potential 225.8% Upside in the Biotech Sector

As ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) captures investor attention, the biotech firm presents a compelling case for those looking to capitalize on significant potential upside. Specializing in innovative treatments for..

Celldex Therapeutics, Inc. (CLDX) Stock Analysis: A Bold Bet with 131.99% Potential Upside

Celldex Therapeutics, Inc. (NASDAQ: CLDX) stands out in the biotechnology sector, leveraging its innovative approach in developing therapeutic antibodies targeting severe inflammatory and autoimmune diseases. With a market capitalization of..

Privia Health Group, Inc. (PRVA) Stock Analysis: A Promising 39.57% Upside Potential

Privia Health Group, Inc. (NASDAQ: PRVA) is attracting significant attention from investors in the healthcare sector due to its robust growth prospects and impressive analyst ratings. As a leader in..

LifeStance Health Group, Inc. (LFST) Stock Analysis: Exploring a 28% Upside Potential

LifeStance Health Group, Inc. (NASDAQ: LFST), a prominent player in the healthcare sector, specifically within the medical care facilities industry, is gaining considerable attention from investors looking for growth opportunities...

DENTSPLY SIRONA Inc. (XRAY) Stock Analysis: A High-Yield Dividend Play Amidst Challenging Metrics

DENTSPLY SIRONA Inc. (NASDAQ: XRAY), a prominent player in the medical instruments and supplies industry, stands out with its attractive dividend yield of 4.94%. However, investors should weigh this income..

Omnicell, Inc. (OMCL) Investor Outlook: Exploring a Potential 57.34% Upside

Omnicell, Inc. (NASDAQ: OMCL), a prominent player in the healthcare sector, is capturing investor attention with its compelling growth potential amidst a challenging market landscape. As a leading provider of..

CG Oncology, Inc. (CGON) Stock Analysis: A 55% Upside Potential in the Biotech Sector

CG Oncology, Inc. (NASDAQ: CGON), a promising player in the biotechnology sector, is capturing the attention of investors with a compelling storyline of innovation and potential growth. Specializing in bladder-sparing..

Kiniksa Pharmaceuticals Interna (KNSA) Investor Outlook: Eyeing a 21% Upside with Strong Buy Ratings

Kiniksa Pharmaceuticals Interna (NASDAQ: KNSA) has been capturing the attention of investors with its compelling growth story and impressive market performance. As a prominent player in the healthcare sector, specifically..

Beam Therapeutics Inc. (BEAM) Stock Analysis: Unlocking a 69% Potential Upside in Genetic Medicine

Beam Therapeutics Inc. (NASDAQ: BEAM) stands at the forefront of the biotechnology sector, focusing on precision genetic medicines aimed at treating serious diseases. With a market capitalization of $2.83 billion,..

NovoCure Limited (NVCR) Stock Analysis: Unveiling a 129% Upside Potential in the Tumor Treating Fields Market

NovoCure Limited (NVCR) is a compelling player in the healthcare sector, specifically within the medical devices industry. With its headquarters in Baar, Switzerland, NovoCure is at the forefront of developing..

Schrodinger, Inc. (SDGR) Investor Outlook: Unpacking a 123% Potential Upside

Schrodinger, Inc. (SDGR) stands at the crossroads of technology and healthcare, offering a compelling investment opportunity in the health information services industry. Based in New York, the company specializes in..

ACADIA Pharmaceuticals Inc. (ACAD) Investor Outlook: Potential 41.67% Upside Amid Robust CNS Drug Portfolio

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a key player in the biotechnology sector, is drawing attention from investors with an impressive projected upside of 41.67% based on analyst target prices. With..

Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: A High-Potential Biotech Play with 27% Upside

Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is a burgeoning player in the biotechnology sector, capturing investor interest with its innovative approach to treating muscle disorders. Headquartered in Boulder, Colorado, this biopharmaceutical..

Brookdale Senior Living Inc. (BKD) Stock Analysis: Unveiling a 15% Potential Upside in the Senior Living Sector

Brookdale Senior Living Inc. (BKD), a prominent player in the healthcare sector focused on medical care facilities, has been making waves with its promising stock performance and growth potential. As..

Select Medical Holdings Corp (SEM) Stock Analysis: 12.33% Potential Upside in Healthcare Sector

Select Medical Holdings Corporation (NYSE: SEM) presents a noteworthy opportunity for investors seeking exposure to the healthcare sector, particularly within the medical care facilities industry. With a current market capitalization..

Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis: Exploring a Promising 20.64% Potential Upside

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a leading player in the healthcare sector, specifically within the specialty and generic drug manufacturing industry, is garnering attention from investors due to its promising..

Travere Therapeutics, Inc. (TVTX) Stock Analysis: Unpacking a 52.25% Potential Upside

Travere Therapeutics, Inc. (NASDAQ: TVTX) is making waves in the biopharmaceutical sector, particularly for investors looking at biotechnology as a fertile ground for growth. With a market capitalization of $2.49..

Tarsus Pharmaceuticals, Inc. (TARS) Stock Analysis: Eye-Catching 52% Upside Potential Sparks Investor Interest

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a burgeoning name in the biotechnology sector, is attracting attention from investors with its promising portfolio of eye care therapeutics and a compelling growth potential...

US Broker Ratings

US Broker Ratings

FTSE 100

Funds